0000000001305107
AUTHOR
Nadezhda Romanchikova
NFAT transcription factors control HIV-1 expression through a binding site downstream of TAR region.
NFAT factors control HIV-1 transcription. We show here that, in addition to binding to two NF-kappaB/NFAT sites within the U3 HIV LTR, NFATc1 and NFATc2 bind to an NFAT site within the LTR's U5 region. Mutations in this site which abolish NFAT binding reduce the ability of NFATs to transactivate LTR-mediated transcription. Mutations in all three NFAT sites strongly interfered with LTR induction, but affected moderately the stimulatory effect of Tat.
Exercise-Induced Extracellular Vesicles Delay the Progression of Prostate Cancer
Increasing evidence suggests that regular physical exercise not only reduces the risk of cancer but also improves functional capacity, treatment efficacy and disease outcome in cancer patients. At least partially, these effects are mediated by the secretome of the tissues responding to exercise. The secreted molecules can be released in a carrier-free form or enclosed into extracellular vesicles (EVs). Several recent studies have shown that EVs are actively released into circulation during physical exercise. Here, we for the first time investigated the effects of exercise-induced EVs on the progression of cancer in an F344 rat model of metastatic prostate cancer. Although we did not observe…
Early and strong antibody responses to SARS-CoV-2 predict disease severity in COVID-19 patients
Abstract Background Antibody response to SARS-CoV-2 is a valuable biomarker for the assessment of the spread of the virus in a population and evaluation of the vaccine candidates. Recent data suggest that antibody levels also may have a prognostic significance in COVID-19. Most of the serological studies so far rely on testing antibodies against spike (S) or nucleocapsid (N) protein, however antibodies can be directed against other structural and nonstructural proteins of the virus, whereas their frequency, biological and clinical significance is unknown. Methods A novel antigen array comprising 30 SARS-CoV-2 antigens or their fragments was developed and used to examine IgG, IgA, IgE and Ig…
Additional file 1 of Early and strong antibody responses to SARS-CoV-2 predict disease severity in COVID-19 patients
Additional file 1: Table S1. Predicted SARS-CoV-2 epitopes expressed in-house. Table S2. Commercial SARS-CoV-2 proteins and human control proteins.
Additional file 2 of Early and strong antibody responses to SARS-CoV-2 predict disease severity in COVID-19 patients
Additional file 2: Fig. S1. Performance of the SARS-CoV-2 antigen array. a A representative image of testing anti-SARS-CoV-2 IgG antibodies in serum from a COVID-19 patient. b Dynamic range of the IgG assay. The antigen array was tested with serial dilutions of a serum sample from a COVID-19 patient. Each dilution was tested in duplicates.